Treatment of primary biliary cholangitis by targeting intestinal flora
10.3969/j.issn.1001-5256.2023.01.029
- VernacularTitle:以肠道菌群为靶点治疗原发性胆汁性胆管炎的临床应用
- Author:
Minghan MA
1
;
Yanqi LIU
1
Author Information
1. Department of Gastroenterology, The Affiliated Hospital of Inner Mongolia Medical University, Huhehot 010050, China
- Publication Type:Review
- Keywords:
Liver Cirrhosis, Biliary;
Gastrointestinal Microbiome;
Therapeutics
- From:
Journal of Clinical Hepatology
2023;39(1):188-191
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cholangitis (PBC) is a progressive cholestatic liver disease targeting biliary epithelial cells, and the concept of "treating diseases by intervening with the gut" has become a research hotspot in recent years. In the future, probiotics may be used to improve the abundance and distribution of intestinal flora, reshape the intestinal microenvironment, and intervene against the progression of PBC. This article reviews the gut microbiota and the clinical application of probiotics, so as to provide ideas for finding new treatment strategies for PBC.
